AstraZeneca’s Ardea Acquisition: A Rich Deal Spurred By Phase III Gout Candidate
This article was originally published in The Pink Sheet Daily
The $1.26 billion buyout comes as the pharma is looking to bolt-on acquisitions to help offset recent late-stage pipeline disappointments and sees Ardea’s lesinurad as a potential improvement in gout therapy, an estimated $2 billion global market.
You may also be interested in...
Also during a busy two-week stretch, AbbVie signs a partnership to co-develop drug conjugate products with CytomX, acquires privately held Stemcentrx, and agrees to a broad-based five-year cancer research collaboration with University of Chicago. Sanofi makes formal bid to acquire Medivation, which is rejected.
What was AstraZeneca's trash is now Ironwood's treasure, as it pays $100m up front, along with milestones and royalties, to acquire gout drug approved in December but not yet launched.
US President Paul Hudson talked in an interview at the J.P. Morgan Healthcare conference about the company’s budding oncology portfolio, upcoming launches and growing optimism as the 2017 return-to-growth goal approaches.